All In Biotech

Drug Trial Radar · NCT06270316

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

A Phase 1/2, Single Dose, Dose Ranging Study of Intravenous AAV5-GLA (AMT-191) in Adult Males With Classic Fabry Disease

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jun 5, 2024

Primary completion

Dec 1, 2027

Study completion Nov 30, 2031

Sponsor

Lead sponsor
UniQure Biopharma B.V.Industry
Sponsor type
Industry
First posted
Feb 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.

Conditions

  • Fabry Disease

Interventions

  • AMT-191Drug

    A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A. Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with Fabry disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of different dose levels of intravenously-administered AMT-191 in Participants with FDTime frame: 60 Months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The Kirklin Clinic Of University of Alabama Birmingham Hospital

    Birmingham, Alabama · Recruiting

  • University of California Los Angeles (UCLA)

    Los Angeles, California · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • MHealth Fairview University of Minnesota Medical Center East Bank

    Minneapolis, Minnesota · Recruiting

  • NYC Health + Hospitals/Metropolitan

    New York, New York · Recruiting

  • Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • University of Utah, Clinical and Translational Sciences Institute

    Salt Lake City, Utah · Recruiting

  • Lysosomal & Rare Disorders Research and Treatment Center, Inc

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.